N-Acylhydrazonic Compounds Treat Amyloid Diseases, Patent Grant
Summary
USPTO granted patent US12600701B2 to Faculdades Católicas for N-acylhydrazonic compounds structurally derived from 1-methyl-1H-imidazole-2-carboxaldehyde for preventing and treating amyloid degenerative aggregopathies including Alzheimer's disease, Parkinson's disease, and type 2 diabetes, as well as non-amyloid conditions such as cataracts. The patent covers four specific compounds and pharmaceutical compositions containing them.
What changed
USPTO issued patent US12600701B2 to Faculdades Católicas, covering a family of N-acylhydrazonic compounds derived from 1-methyl-1H-imidazole-2-carboxaldehyde and their use in treating amyloid and non-amyloid degenerative aggregopathies. The compounds function as metal-protein interaction attenuators to prevent or decrease protein oligomerization.
Pharmaceutical companies and researchers developing treatments for Alzheimer's, Parkinson's, type 2 diabetes, cataracts, or related protein aggregation diseases should note this patent grant, as it may affect freedom-to-operate considerations for competing therapeutic approaches in this chemical space.
What to do next
- Monitor for updates
Archived snapshot
Apr 14, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
N-acylhydrazonic compounds, use in the treatment of amyloid and non-amyloid degenerative aggregopathies, and pharmaceutical composition
Grant US12600701B2 Kind: B2 Apr 14, 2026
Assignee
FACULDADES CATÓLICAS
Inventors
Nicolás Adrián Rey, Daphne Schneider Cukierman Rey
Abstract
The present invention relates to a family of N-acylhydrazonic compounds structurally derived from 1-methyl-1H-imidazole-2-carboxaldehyde, or pharmaceutically acceptable salts thereof, and the use of said compounds to prevent and/or treat amyloid (such as Alzheimer's, Parkinson's and type 2 diabetes) and non-amyloid (such as cataracts) degenerative aggregopathies These compounds act as attenuators of the metal-protein interaction, preventing and/or decreasing protein oligomerization through competition with the target peptide or protein for the binding of physiological metal ions and, possibly, by modulating the protein-protein interaction itself. The invention also details four compounds specifically described as examples of N-acylhydrazones derived from 1-methyl-1H-imidazole-2-carboxaldehyde, namely: 1-methyl-1H-imidazole-2-carboxaldehyde isonicotinoyl hydrazone, 1-methyl-1H-imidazole-2-carboxaldehyde benzoyl hydrazone, 1-methyl-1H-imidazole-2-carboxaldehyde 2-furoyl hydrazone and 1-methyl-1H-imidazole-2-carboxaldehyde 2-thiophenyl hydrazone. The current application also comprises pharmaceutical compositions.
CPC Classifications
C07D 233/64 C07D 401/12 C07D 405/12 C07D 409/12
Filing Date
2021-03-15
Application No.
17912427
Claims
18
Related changes
Get daily alerts for USPTO Patent Grants - Organic Chemistry (C07D)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Organic Chemistry (C07D) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.